Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20837, USA.
Lancet Neurol. 2011 Oct;10(10):942-6. doi: 10.1016/S1474-4422(11)70196-X.
Much basic research into disease mechanisms has made use of genetic findings to model and understand aetiology. Broad success has been achieved in finding disease-linked mutations with traditional positional cloning approaches; however, because of the requirements of this method, these successes have been limited by the availability of large, well characterised families. Because of these and other restrictions the genetic basis of many diseases, and diseases in many families, remains unknown.
Exome sequencing uses DNA-enrichment methods and massively parallel nucleotide sequencing to comprehensively identify and type protein-coding variants throughout the genome. Coupled with growing databases that contain known variants, exome sequencing makes identification of genetic mutations and risk factors possible in families and samples that were deemed insufficiently informative for previous genetic studies. Not only does exome sequencing enable identification of mutations in families that were undetectable with linkage and positional cloning methods, but compared with these methods, it is also much quicker and cheaper. Use of exome sequencing has so far been successful in many rare diseases. WHERE NEXT?: Exome sequencing is being adopted widely and we can expect an abundance of mutation discovery, similar to the deluge of genome-wide-association findings reported over the past 5 years; it is expected to enable the discovery of not only rare causal variants, but also protein-coding risk variants. This method will have application in both the research and clinical arenas and sets the scene for the use of whole-genome sequencing.
许多疾病机制的基础研究都利用遗传发现来模拟和理解病因。通过传统的定位克隆方法发现与疾病相关的突变已经取得了广泛的成功;然而,由于这种方法的要求,这些成功受到了大型、特征良好的家族的可用性的限制。由于这些和其他限制,许多疾病以及许多家族的疾病的遗传基础仍然未知。
外显子组测序使用 DNA 富集方法和大规模并行核苷酸测序,全面识别和分型整个基因组中的蛋白编码变异。与包含已知变异的不断增长的数据库相结合,外显子组测序使得在以前的遗传研究中被认为信息量不足的家族和样本中,鉴定遗传突变和风险因素成为可能。外显子组测序不仅能够识别用连锁和定位克隆方法无法检测到的家族中的突变,而且与这些方法相比,它也更快、更便宜。外显子组测序的应用迄今为止在许多罕见疾病中都取得了成功。
下一步是什么?:外显子组测序正在被广泛采用,我们可以预期会有大量的突变发现,就像过去 5 年报告的全基因组关联发现的洪流一样;预计它不仅能够发现罕见的因果变异,还能够发现编码蛋白的风险变异。这种方法将在研究和临床领域得到应用,并为全基因组测序的应用奠定基础。